Design, syntheses and biological evaluation of natural product aiphanol derivatives and analogues: discovery of potent anticancer agents.

[1]  L. Yao,et al.  Aiphanol, a multi-targeting stilbenolignan, potently suppresses mouse lymphangiogenesis and lymphatic metastasis , 2022, Acta Pharmacologica Sinica.

[2]  B. Stockwell,et al.  Discovery of Anticancer Agents of Diverse Natural Origin. , 2022, Journal of natural products.

[3]  L. Yao,et al.  A multi-targeting natural product, aiphanol, inhibits tumor growth and metastasis. , 2022, American journal of cancer research.

[4]  C. Shou,et al.  Aiphanol, a native compound, suppresses angiogenesis via dual-targeting VEGFR2 and COX2 , 2021, Signal Transduction and Targeted Therapy.

[5]  M. Vicente,et al.  Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR) , 2021, Molecules.

[6]  R. Roskoski.  Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update. , 2021, Pharmacological research.

[7]  David J Newman,et al.  Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. , 2020, Journal of natural products.

[8]  Junjie Yu,et al.  Synthesis and Anticancer Evaluation of Amido-Derivative of Hydnocarpin D , 2020 .

[9]  Zongru Guo,et al.  The modification of natural products for medical use , 2016, Acta pharmaceutica Sinica. B.

[10]  R. Su,et al.  Gram Scale Syntheses of (-)-Incarvillateine and Its Analogs. Discovery of Potent Analgesics for Neuropathic Pain. , 2016, Journal of medicinal chemistry.

[11]  E. Aranda,et al.  Simultaneous Inhibition of EGFR/VEGFR and Cyclooxygenase-2 Targets Stemness-Related Pathways in Colorectal Cancer Cells , 2015, PloS one.

[12]  Lin Zhao,et al.  Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs , 2015, Oncotarget.

[13]  Nimit L. Patel,et al.  COX-2 Inhibition Potentiates Antiangiogenic Cancer Therapy and Prevents Metastasis in Preclinical Models , 2014, Science Translational Medicine.

[14]  Zhihong Li,et al.  Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo. , 2014, Oncology reports.

[15]  J. McCubrey,et al.  Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells , 2013, PloS one.

[16]  Shuo Xu,et al.  Chemical Constituents from the Rhizomes of Smilax glabra and Their Antimicrobial Activity , 2013, Molecules.

[17]  Masayo Umebayashi,et al.  Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro. , 2013, Anticancer research.

[18]  S. Goldberg,et al.  Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts , 2013, British Journal of Cancer.

[19]  C. Shou,et al.  Mitochondrial apoptosis contributes to the anti-cancer effect of Smilax glabra Roxb. , 2011, Toxicology letters.

[20]  V. Petito,et al.  New C-23 modified of silybin and 2,3-dehydrosilybin: synthesis and preliminary evaluation of antioxidant properties. , 2011, Bioorganic & medicinal chemistry letters.

[21]  J. Spratlin,et al.  The role of bevacizumab in colorectal cancer: understanding its benefits and limitations , 2011, Expert opinion on biological therapy.

[22]  V. Křen,et al.  Chemoenzymatic preparative separation of silybins A and B , 2009 .

[23]  O. Stoeltzing,et al.  The direct effects of anti-vascular endothelial growth factor therapy on tumor cells. , 2007, Clinical colorectal cancer.

[24]  M. Banwell,et al.  Biomimetic Preparation of the Racemic Modifications of the Stilbenolignan Aiphanol and Three Congeners , 2007 .

[25]  Curzio Rüegg,et al.  Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis. , 2004, Biochimica et biophysica acta.

[26]  G. Tortora,et al.  Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy , 2004, Clinical Cancer Research.

[27]  C. Parish,et al.  Convergent synthesis and preliminary biological evaluations of the stilbenolignan (+/-)-aiphanol and various congeners. , 2003, Organic & biomolecular chemistry.

[28]  A. Kuboki,et al.  Total Synthesis of (.+-.)-Aiphanol, a Novel Cyclooxygenase-inhibitory Stilbenolignan , 2003 .

[29]  J. Pezzuto,et al.  A novel cyclooxygenase-inhibitory stilbenolignan from the seeds of Aiphanes aculeata. , 2001, Organic letters.